Pharmacotherapy is an important component of treatment for children and adolescents with bipolar disorder. The body of evidence supporting safe and effective treatments in this population is growing. Available data provide information on the risks and benefits of pharmacologic agents used for acute manic, mixed, and depressive episodes as well as for maintenance treatment. Lithium, anticonvulsants, and antipsychotics comprise the armamentarium for treating pediatric bipolar disorder. When selecting treatment, clinicians must consider the efficacy and side effect profile of potential pharmacotherapies, as well as the patient’s history, including the presence of comorbidities, in order to develop a treatment plan that will ensure optimal outcomes.
Supplement Article September 15, 2016
Evidence-Based Pharmacologic Treatment of Pediatric Bipolar Disorder
J Clin Psychiatry 2016;77(suppl E1):e02
Article Abstract
Vol 86 • 2025 • Number 3
Read the Current Issue
Original Research
Treatment Use and Preference in a Diverse Sample of Women With Mood Disorders
Original Research
Klotho and Matrix Metalloproteinase-9 Levels and Their Association with Inhibitory Dyscontrol in Adolescents with First-Episode Major Affective Disorders
Original Research
Niacin-Induced Response in Early Psychosis
Original Research
Early Ketamine Response Reduces Suicidal Events at 3 Months
Letter to the Editor
Suicide Risk among Patients with Bipolar Disorder: Sleep Disruption versus Benzodiazepine Use
Original Research
